- Company
- It is difficult to secure domestic funding for bio ventures
- by Hwang, Jin-joon Apr 10, 2023 05:51am
- "It is not easy to change KDDF's funding method. It is possible to raise funds only when investors flock to it, but in order to attract funds from the United States, we are planning an event to invite major US VCs to invest in Korean bio ventures in July. are doing." Muk Hyun-sang, head of KDDF, made this announcement at a press conference he
- Company
- GemVax’s Alzheimer’s Tx GV1001 receives IND approval
- by Kim, Jung-Ju Apr 7, 2023 05:55am
- On the 4th, GemVax & KAEL announced that it had received investigational new drug (IND) approval for the Phase II trial of its Alzheimer’s treatment candidate, GV1001, in 7 European countries as planned. With its procedures for clinical trial approvals in the 7 European countries complete, the company plans to accelerate the clinical tri
- Company
- The dilemma of price cuts for Lipiodol and Fattiodol
- by Nho, Byung Chul Apr 7, 2023 05:55am
- There are many opinions of concern that the two items of X-ray contrast medium registered as essential medicines may fall into a situation where supply is not possible. According to the industry, price cuts are scheduled for Lipiodol and Fattiodol on the 1st of next month, and the price of raw materials for these products is high. The origin
- Company
- Rise of new drugs... subject of NA and public petitions
- by Eo, Yun-Ho Apr 7, 2023 05:54am
- Specific product names of new drugs are being mentioned at the National Assembly audit and public petitions calling for the application of reimbursement for specific drugs have gathered 50,000 consents. Such activities, which would not have happened 5 years ago, are actually arising in Korea. The emergence of government affairs (GA) and p
- Company
- LG Chem releases DPP-4+SGLT-2 combo Zemidapa Tab
- by Kim, Jin-Gu Apr 6, 2023 05:53am
- On the 4th, LG Chem announced it will be releasing its new antidiabetic combination drug ‘Zemidapa Tab’ on the 8th. Zemidapa is a fixed-dose combination of the DPP-4 inhibitor class market leader Zemiglo (gemigliptin) and SGLT-2 inhibitor class market leader dapagliflozin (Product name: Forxiga). Zemidapa is the only option that offers
- Company
- NeuroBo, a subsidiary of Dong-A ST, applies for NASH candida
- by Apr 6, 2023 05:53am
- Dong-A ST announced on the 4th that its US subsidiary NeuroBo Pharmaceuticals has applied to the US Food and Drug Administration (FDA) for a phase 2 clinical trial plan for NASH treatment candidate DA-1241. This clinical trial will be conducted for 16 weeks on 87 patients with NASH. It is a multicenter, randomized, double-blind, placebo-contr
- Company
- Zuellig Pharma Korea turns profitable in 6 years
- by Apr 6, 2023 05:53am
- Zuellig Pharma Korea, a global drug distribution company, escaped from complete capital impairment last year (total capital was negative). Operating profit also turned to black for the first time in six years. We are concentrating our efforts on improving performance by significantly reducing SG&A. According to the Financial Supervisory Servi
- Company
- Onureg, PO acute leukemia drug, is scheduled to be proposed
- by Eo, Yun-Ho Apr 6, 2023 05:53am
- Onureg, a maintenance therapy for acute myeloid leukemia, is on its way to entering insurance coverage. As a result of the coverage, Onureg is scheduled to be presented to the Pharmaceutical Reimbursement Evaluation Committee of the Health Insurance Review and Assessment Service on the 6th. It has been about four months since the passage of t
- Company
- Patients and policy are trending in the pharma industry
- by Eo, Yun-Ho Apr 6, 2023 05:53am
- The opening of new positions that didn’t exist before indicates the considerable need for the positions. Recently, Korean subsidiaries of multinational pharmaceutical companies that mainly supply new drugs have opened up two new positions - GA (Government Affairs) and PA (Patient Advocacy). The changes seem to be in line with the trend
- Company
- Active M&A for global cell and gene therapy
- by Hwang, Jin-joon Apr 5, 2023 05:47am
- In the field of cell and gene therapy, which is considered a next-generation drug, an M&A worth 3.4 trillion won was completed. Domestic biopharmaceutical companies are conducting R&D in the field of cell and gene therapy as a future food source. CDMO companies are entering the CDMO business for cell and gene therapy through M&A and factory e
